The Alexandria Venture Investments-backed genetic disease therapy developer is floating above its range having increased the number of shares in the offering.
US-based genetic disease drug developer Stoke Therapeutics will raise approximately $142m when it floats later today, providing an exit for life sciences real estate investment trust Alexandria Real Estate Equities.
The company priced its shares at $18.00 each, above the IPO’s $14 to $16 range. It also increased the number of shares from 6.7 million to just over 7.89 million and is listing on the Nasdaq Global Select Market, at a valuation of about $566m.
Stoke is developing therapies that…
